论文部分内容阅读
目的:探讨针对免疫介导性肾脏病患者,对其采用来氟米特进行辅助治疗的效果表现。方法:选取我院2010年6月~2012年6月免疫介导性肾脏病患者80例,通过抽签法将所有患者随机分成两组,组别名称设为A1组(观察组40例)与A2组(对照组40例)。针对A1组患者对其采用激素+来氟米特进行治疗,针对A2组患者对其采用激素+环磷酰胺进行治疗。对比两组患者在规定时间完成治疗后的效果表现。结果:最终对比两组完成治疗后的总有效率发现,A1组患者优于A2组患者显著(P<0.01)。完成治疗后A1组、A2组患者体内HSA(血清白蛋白)水平都有程度有所不同的上升(P<0.05,P<0.01)。A1组患者改善程度显著优于A2组患者(P<0.01)。A1组患者出现不良反应的概率以及不良反应的严重程度都显著低于A2组患者(P<0.01)。结论:探讨针对免疫介导性肾脏病患者,采用来氟米特进行辅助治疗,效果表现显著。
Objective: To investigate the effect of adjuvant leflunomide in patients with immune-mediated kidney disease. Methods: Eighty patients with immune-mediated renal disease from June 2010 to June 2012 in our hospital were enrolled. All patients were randomly divided into two groups according to the method of lottery. The group names were A1 group (observation group 40 cases) and A2 Group (control group 40 cases). Patients in group A1 were treated with hormone + leflunomide, and patients in group A2 were treated with hormone + cyclophosphamide. Comparison of two groups of patients in the prescribed time to complete the treatment after the performance. Results: The final total effective rate of two groups after completion of treatment found that patients in group A1 were superior to those in group A2 (P <0.01). After treatment, the level of HSA (serum albumin) in patients in groups A1 and A2 increased to some extent (P <0.05, P <0.01). Patients in group A1 improved significantly more than those in group A2 (P <0.01). The incidence of adverse reactions and the severity of adverse reactions in patients in group A1 were significantly lower than those in patients in group A2 (P <0.01). Conclusion: To investigate the immune-mediated renal disease patients, the use of leflunomide adjuvant therapy, the effect was significant.